(18)F-FDG PET-CT for Surveillance of Brazilian Patients with Li-Fraumeni Syndrome

• Published in: Frontiers in oncology 2015, Vol.5, p.38-38
• Main Authors: Nogueira, Sonia Tereza Santos, Lima, Eduardo Nóbrega Pereira, Nóbrega, Amanda França, Torres, Ivone Do Carmo Gonçalves, Cavicchioli, Marcelo, Hainaut, Pierre, Achatz, Maria Isabel Waddington
• Format: Article
• Language: English
• Subjects: Life Sciences; Santé publique et épidémiologie
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2015.00038

To evaluate the effectiveness of (18)F-Fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) for detecting early cancer in carriers of germline TP53 mutation, the genetic defect underlying Li-Fraumeni and related syndromes, which predisposes to many forms of cancer throughout life. A total of 30 adult patients from six families with germline TP53 mutations were recruited. These patients did not have a diagnosis of cancer in the 24 months preceding the study. Anomalous concentrations from whole-body (18)F-FDG-PET/CT were assessed by two independent experts. Suspicious lesions were excised and subjected to pathological examination. A total of 6/30 patients showed abnormal (18)F-FDG-concentration. Confirmation studies revealed three cases of cancer, including one lung cancer, one ovarian cancer, and one disseminated breast cancer. Three patients had non-malignant lesions (one Bartholin's cyst and two cases of reactive lymph nodes). (18)F-FDG-PET/CT is effective in detecting cancer in subjects who are asymptomatic according to current screening guidelines. These results further suggest that (18)F-FDG-PET/CT is an appropriate method for surveillance of cancer risk in TP53 mutation carriers.